Trial Profile
A Phase 1, Single Center, Biomarker Study in Healthy Subjects Receiving Single Doses of CAT-1004.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Jul 2022
Price :
$35
*
At a glance
- Drugs Edasalonexent (Primary) ; Docosahexaenoic acid; Salsalate
- Indications Duchenne muscular dystrophy; Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 11 Jan 2017 Primary endpoint (Change in nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) activity p65 following ex vivo lipopolysaccharide stimulation) has been met.
- 11 Jan 2017 Combined results from three phase I trials published in the Journal of Clinical Pharmacology
- 11 Feb 2013 Combined results from three phase I trials were reported in a Catabasis media release.